Medical technology company Nyxoah has officially launched its Genio system, a small implant that has the potential to treat obstructive sleep apnea (OSA) without the need for a CPAP machine.

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

Sleep apnea affects millions globally, often lurking undetected until it begins impacting overall health. While high blood ...

"Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in adults with obesity." ...

July 23, 2024 — Nearly 40 million adults in the U.S. have sleep apnea, and more than 30 million of them use a continuous positive airway pressure (CPAP) machine while sleeping. However ...

There are many consequences of untreated OSA, and all of these are more likely with more-severe obstruction. Because people with OSA don't sleep well, they are at a higher risk for motor vehicle ...

FDA approves Zepbound for obstructive sleep apnea in obese individuals Discover how this weight-loss drug reduces symptoms ...

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity.

The U.S. Food and Drug Administration (FDA) has approved Zepbound, a prescription weight-loss medication, as the first drug ...

Obstructive sleep apnea (OSA) is a common sleep disorder characterized by intermittent airway blockages during sleep, leading ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...